George Warimwe/Wellcome Open Res

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.Hamaluba M, Sang S, Orindi B, Njau I, Karanja H, Kamau N, Gitonga JN, Mugo D, Wright D, Nyagwange J, Kutima B, Omuoyo D, Mwatasa M, Ngetsa C, Agoti C, Cheruiyot S, Nyaguara A, Munene M, Mturi N, Oloo E, Ochola-Oyier L, Mumba N, Mauncho C, Namayi R, Davies A, Tsofa B, Nduati EW, Aliyan N, Kasera K, Etyang A, Boyd A, Hill A, Gilbert S, Douglas A, Pollard A, Bejon P, Lambe T, Warimwe G
Wellcome Open Res, (2023). 8:182

Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya.Nyagwange J, Ndwiga L, Muteru K, Wamae K, Tuju J, Testing Team C, Kutima B, Gitonga J, Karanja H, Mugo D, Kasera K, Amoth P, Murunga N, Babu L, Otieno E, Githinji G, Nokes DJ, Tsofa B, Orindi B, Barasa E, Warimwe G, Agoti CN, Bejon P, Ochola-Oyier LI
Wellcome Open Res, (2022). 7:69

Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data.Ojal J, Brand SPC, Were V, Okiro EA, Kombe IK, Mburu C, Aziza R, Ogero M, Agweyu A, Warimwe GM, Uyoga S, Adetifa IMO, Scott JAG, Otieno E, Ochola-Oyier LI, Agoti CN, Kasera K, Amoth P, Mwangangi M, Aman R, Ng'ang'a W, Tsofa B, Bejon P, Barasa E, Keeling MJ, Nokes DJ
Wellcome Open Res, (2021). 6:127